3 Biotech Losers: Sarepta Therapeutics Inc (SRPT), Theravance Inc (THRX), And Cempra Inc (CEMP)
New York, NY – GDP INSIDER – 01/07/2014.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s CEO, Chris Garabedian, is scheduled to offer an overview of the company at an important investor event in San cialis side effects Francisco in the coming week. Garabedian will present at the 33rd edition of Annual J.P. Morgan Healthcare Conference on January 15.
Sarepta Therapeutics Inc (NASDAQ:SRPT) letrozole vs clomid is active in innovative drug development based on RNA. The conference is expected to give the company a much-needed exposure, which could also attract funding for its various projects.
Meanwhile, a disgruntled shareholder in Sarepta Therapeutics Inc (NASDAQ:SRPT) has filed a lawsuit against the company in Massachusetts. The investor claims various violations by the company that border on dissemination of misleading statements, which later caused losses when the facts were revealed.
Theravance Inc (NASDAQ:THRX), which recently announced options to purchase shares for certain of its officers, saw its shares falling, but female viagra that shouldn’t come as a surprise as it was expected. However, what happens next is the most important thing to consider. The fall in the share price of generic levitra Theravance followed the completion of the spin-off of Theravance Biopharma (NASDAQ:TBPH).
It seems investors have not quite understood what is going on following the spin-off transaction. However, the point to note is that Theravance Inc (NASDAQ:THRX) has now become a company focused on royalty payments linked to its various drug projects and partnerships. It will be paying dividends as well. On the other hand, the separated entity Theravance Biopharma, will be a clinical pure play, but caverta brand online currently has no products on the market and future dividends are not assured.
Cempra Inc (NASDAQ:CEMP) underwent a generic viagra significant correction following a gain triggered by positive late-stage trial data for its antibiotic drug candidate, solithromycin. The company reported that an oral version of the treatment met the required primary end point.
viagra falls The drug is a potential blockbuster given that bacteria are increasingly becoming resistant to existing therapies.
There are speculations that
Cempra Inc (NASDAQ:CEMP) could be targeted for acquisitions by the Big Pharma companies seeking to secure their revenue in the antibiotic space. However, the company’s CEO, Prabha Fernandes, doesn’t look excited by a partnership deal currently.
UltimateStockAlerts.com provides investors and traders with trading strategies via text message plavix generic and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.
UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet viagra 100mg companies for its free e-newsletter subscribers.
Disclosure: UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due canadian online pharmacy calls diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.